Figure 1.

Achievement of American College of Rheumatology Pediatric (ACR Pedi) 30%, 50%, and 70% improvement response to phase II dose-escalating study of tocilizumab in 11 children with systemic juvenile idiopathic arthritis (SJIA).

The tocilizumab treatments (three doses each at 2, 4, and 8 mg/kg) yielded significantly better outcomes for all endpoints according to the ACR Pedi core set criteria. Of the 11 children requiring 2 mg/kg tocilizumab, seven (63.6%) achieved both 30% and 50% improved responses, while one child (9.1%) achieved a 70% improved response at the last observation. Seven of the eight children (87.5%) infused three times with 4 mg/kg tocilizumab had both 30% and 50% improved responses, and four of these eight children (50.0%) had a 70% improvement response at the last observation. All three children who received three doses of 8 mg/kg tocilizumab had 30%, 50%, and 70% improvement responses 2 weeks after the last infusion of tocilizumab [Yokota et al. 2005].